These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31902122)

  • 21. Use of ristocetin cofactor activity in the management of von Willebrand disease.
    Ewenstein BM
    Haemophilia; 2001 Jan; 7 Suppl 1():10-5. PubMed ID: 11240613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New treatments of von Willebrand disease: plasma derived von Willebrand factor concentrates.
    Menache D; Aronson DL
    Thromb Haemost; 1997 Jul; 78(1):566-70. PubMed ID: 9198217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
    Dunkley S; Baker RI; Pidcock M; Price J; Seldon M; Smith M; Street A; Maher D; Barrese G; Stone C; Lloyd J
    Haemophilia; 2010 Jul; 16(4):615-24. PubMed ID: 20331755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients.
    Federici AB; Bucciarelli P; Castaman G; Baronciani L; Canciani MT; Mazzucconi MG; Morfini M; Rocino A; Schiavoni M; Oliovecchio E; Iorio A; Mannucci PM
    Semin Thromb Hemost; 2011 Jul; 37(5):511-21. PubMed ID: 22102194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylaxis in von Willebrand disease.
    Franchini M; Targher G; Lippi G
    Ann Hematol; 2007 Oct; 86(10):699-704. PubMed ID: 17634944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction between VWF and FVIII in treating VWD.
    Miesbach W; Berntorp E
    Eur J Haematol; 2015 Nov; 95(5):449-54. PubMed ID: 25605439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type 2A von Willebrand disease and systemic sclerosis: Vonicog alfa reduced gastrointestinal bleeding.
    Korsten P; Wallbach M; Binder C
    Res Pract Thromb Haemost; 2020 Oct; 4(7):1230-1234. PubMed ID: 33134789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates.
    Fressinaud E; Veyradier A; Sigaud M; Boyer-Neumann C; Le Boterff C; Meyer D
    Br J Haematol; 1999 Sep; 106(3):777-83. PubMed ID: 10468873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Von Willebrand disease - the 'Dos' and 'Don'ts' in surgery.
    Miesbach W; Berntorp E
    Eur J Haematol; 2017 Feb; 98(2):121-127. PubMed ID: 27622750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Von Willebrand Disease and Pregnancy: A Review of Evidence and Expert Opinion.
    Reynen E; James P
    Semin Thromb Hemost; 2016 Oct; 42(7):717-723. PubMed ID: 27648611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
    Windyga J; von Depka-Prondzinski M;
    Thromb Haemost; 2011 Jun; 105(6):1072-9. PubMed ID: 21437358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis and management of von Willebrand disease in Australia.
    Favaloro EJ; Bonar R; Favaloro J; Koutts J
    Semin Thromb Hemost; 2011 Jul; 37(5):542-54. PubMed ID: 22102198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
    Castaman G; Tosetto A; Federici AB; Rodeghiero F
    Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis and management of von Willebrand disease in Iran.
    Cohan N; Karimi M
    Semin Thromb Hemost; 2011 Jul; 37(5):602-6. PubMed ID: 22102206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder.
    Favaloro EJ
    Semin Thromb Hemost; 2011 Jul; 37(5):440-55. PubMed ID: 22102186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy.
    Vinayagam S; Simons LR; Chowdary P; Thurlow P; Brooks SV; Riddell AF
    Haemophilia; 2014 Jul; 20(4):e304-10. PubMed ID: 24758424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of current perioperative management with Haemate
    Hazendonk HCAM; Heijdra JM; de Jager NCB; Veerman HC; Boender J; van Moort I; Mathôt RAA; Meijer K; Laros-van Gorkom BAP; Eikenboom J; Fijnvandraat K; Leebeek FWG; Cnossen MH;
    Haemophilia; 2018 May; 24(3):460-470. PubMed ID: 29573506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study.
    Miesbach W; Krekeler S; Wolf Z; Seifried E
    Thromb Res; 2015 Mar; 135(3):479-84. PubMed ID: 25595881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of human recombinant, plasma-derived and porcine von Willebrand factor in pigs with severe von Willebrand disease.
    Roussi J; Turecek PL; André P; Bonneau M; Pignaud G; Bal dit Sollier C; Schlokat U; Dorner F; Schwarz HP; Drouet L
    Blood Coagul Fibrinolysis; 1998 Jun; 9(4):361-72. PubMed ID: 9690808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.